Zydus Lifesciences to buy Assertio for ₹1,592cr and add Rolvedon
NewsBytes | May 14, 2026 1:39 AM CST
Assertio will be delisted from Nasdaq
The deal wraps up by Q2 2026 and means Assertio will be delisted from Nasdaq. Their earlier merger with Garda is off the table since Zydus's offer didn't need extra financing or regulatory hurdles.
Assertio brings a mix of oncology, neurology, and pain management drugs, built through deals and acquisitions, which fits right into Zydus's global strategy.
As Dr. Sharvil Patel (Zydus MD) puts it, this step supports its goal of expanding specialty medicines worldwide.
READ NEXT
-
I tried the Home Bargains bakery - one 69p item was better than M&S
-
Morrisons adds NHS cancer health warning to 3 bath and shower products
-
EU is drawing up 'Farage as PM' plans while Labour leadership rivals vow to reverse Brexit
-
MS Dhoni's Potential Farewell at Chepauk: CSK vs SRH IPL 2026 Showdown
-
RRB ALP Recruitment 2026: Recruitment for 11,127 Posts in Railways Begins; Several Major Changes Introduced—From Syllabus to Merit..
